# Peptidream

> Peptidream is a VC fund in Tokyo backing Pharmaceutical and Medical. See 6 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 6
- Last investment: Apr 2025
- Lead investor: 17%
- Last updated: Sep 2026
- Website: https://www.peptidream.com/

PeptiDream is a biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hitcandidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics.

## Contacts

5 contacts available for Peptidream. Shizune tracks 5 team members at Peptidream. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/peptidream?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 3 | 50% |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Oncology | 1 | 17% |
| Biotechnology | 1 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 2 | 33% |
| Corporate Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 3 | 50% |
| United States | 1 | 17% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hiroaki Suga | Co-Founder | 0 | — |
| Keiichi Masuya | COO | 2 | — |
| Kiyofumi Kaneshiro | Executive Vice President Director – Board Member | 2 | — |
| Patrick C. Reid | Co-Founder, President & CEO | 0 | — |
| Shinichiro Fujiie | Director, Executive Officer | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Linqmed | Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $15.9M | Series B | Apr 09, 2025 |  |
| Linqmed | Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $9.5M | Series B | Jan 10, 2025 |  |
| Linqmed | Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $4.8M | Series A | Dec 22, 2023 |  |
| Kleo | Kleo is developing two types of small molecules to treat cancer, infectious diseases, and a broad range of indications: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). They believe their technology represents a breakthrough in safer, more efficacious, and more convenient treatment options. | $21M | Series B | Nov 14, 2018 |  |
| Alivexis | Modulus Discovery is a private Tokyo-based preclinical stage drug discovery company focused on rapid design and generation of small molecule clinical candidates for a range of high-value disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The international team at Modulus iscomprised of drug design and disease biology experts with previous R&D experience at global pharmaceutical, biotechnology , and computational technology firms. | $7.2M | Series A | Aug 09, 2018 |  |
| PeptiStar | PeptiStar is a CDMO (Contract Development and Manufacturing Organization) for peptide APIs, from traditional peptides to constrained peptides including macrocyclic and stapled peptides containing non-natural amino acids. PeptiStar is a technology-based company that provides its customers with high value-added services through its innovativemanufacturing technologies. | $186.3M | Corporate Round | Apr 18, 2018 |  |

6 of 6 investments shown.

## Co-investors
- [DBJ Capital](https://shizune.co/investors/profile/dbj-capital) — VC Fund, 4 deals together
- [JIC Venture Growth Investments](https://shizune.co/investors/profile/jic-venture-growth-investments) — VC Fund, 2 deals together
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund, 2 deals together
- Osaka-Kansai Expo Revitalization Investment — VC Fund, 2 deals together
- [Axil Capital](https://shizune.co/investors/profile/axil-capital) — VC Fund, 1 deal together
- Biohaven Pharmaceutical — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Peptidream invest in?

Peptidream invests primarily in Pharmaceutical, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Peptidream?

Public channels for Peptidream include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Peptidream?

The team at Peptidream includes Hiroaki Suga (Co-Founder), Keiichi Masuya (COO) and Kiyofumi Kaneshiro (Executive Vice President Director – Board Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co